Drug Approval | October 18, 2021
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
Subscribe To Our Newsletter & Stay Updated
